Lees A J
National Hospitals for Nervous Diseases, London, U.K.
J Neural Transm Suppl. 1987;25:157-62.
Selegiline hydrochloride (-)-deprenyl is now established as a safe and valuable adjuvant therapy in the management of Parkinson's disease. About fifty per cent of patients with mild levodopa-induced fluctuations are improved by the addition of 10 mg a day of selegiline and there may be associated relief of nocturnal and early morning disabilities. This effect is usually apparent within a week of starting treatment and is sustained in the majority of responders for at least one year, after that oscillations progressively return. Compared with other anti-parkinsonian drugs this medication is relatively easy to use and has few adverse side-effects. Unlike conventional monoamine oxidase inhibitors, dietary restrictions of tyramine are unnecessary and rises in blood pressure do not occur when it is used together with L-dopa. Selegiline also has mild L-dopa sparing effects (100-200 mg per day) and it may also increase alertness, drive and motivation (Lees et al., 1977). Some of the more controversial issues relating to selegiline will be discussed in this article.
盐酸司来吉兰（-）-丙炔苯丙胺现已被确立为帕金森病治疗中一种安全且有价值的辅助疗法。约50%轻度左旋多巴诱导的运动波动患者，通过每日加用10毫克司来吉兰可得到改善，且夜间及清晨的功能障碍可能也会随之缓解。这种效果通常在开始治疗一周内显现，大多数有反应者至少可持续一年，之后症状会逐渐恢复波动。与其他抗帕金森病药物相比，这种药物使用相对简便，副作用较少。与传统单胺氧化酶抑制剂不同，无需限制食物中的酪胺摄入，与左旋多巴合用时也不会出现血压升高。司来吉兰还具有轻度节省左旋多巴的作用（每日100 - 200毫克），并且可能还会提高警觉性、驱动力和积极性（利斯等人，1977年）。本文将讨论一些与司来吉兰相关的更具争议性的问题。
